Elham Zendedel,1,*Shiva Asadpour,2
1. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran 2. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran
Introduction: The prevalence of cardiovascular illnesses, as well as a scarcity of suitable autologous tissues, has prompted and accelerated the development of tissue-engineered vascular grafts (TEVGs). Vascular tissue engineering has the potential to have a substantial influence on a wide range of clinical issues. Despite significant research into synthetic polymers as vascular engineering alternatives, they fall short of solving the biological difficulties at the blood–material interface. To overcome these problems and improve the long-term patency of vascular grafts, several tissue engineering methods have developed. The seeding of vascular cells onto scaffolds and the development of bioactive polymers for in situ arterial regeneration have both shown promising outcomes. The difficulties in developing engineered constructs that meet the physiologic, immunologic, and manufacturing requirements of engineered vasculature will be discussed.
Methods: The prevalence of cardiovascular illnesses, as well as a scarcity of suitable autologous tissues, has prompted and accelerated the development of tissue-engineered vascular grafts (TEVGs). Vascular tissue engineering has the potential to have a substantial influence on a wide range of clinical issues. Despite significant research into synthetic polymers as vascular engineering alternatives, they fall short of solving the biological difficulties at the blood–material interface. To overcome these problems and improve the long-term patency of vascular grafts, several tissue engineering methods have developed. The seeding of vascular cells onto scaffolds and the development of bioactive polymers for in situ arterial regeneration have both shown promising outcomes. The difficulties in developing engineered constructs that meet the physiologic, immunologic, and manufacturing requirements of engineered vasculature will be discussed.
Results: The prevalence of cardiovascular illnesses, as well as a scarcity of suitable autologous tissues, has prompted and accelerated the development of tissue-engineered vascular grafts (TEVGs). Vascular tissue engineering has the potential to have a substantial influence on a wide range of clinical issues. Despite significant research into synthetic polymers as vascular engineering alternatives, they fall short of solving the biological difficulties at the blood–material interface. To overcome these problems and improve the long-term patency of vascular grafts, several tissue engineering methods have developed. The seeding of vascular cells onto scaffolds and the development of bioactive polymers for in situ arterial regeneration have both shown promising outcomes. The difficulties in developing engineered constructs that meet the physiologic, immunologic, and manufacturing requirements of engineered vasculature will be discussed.
Conclusion: The difficulties in developing engineered constructs that meet the physiologic, immunologic, and manufacturing requirements of engineered vasculature will be discussed.